Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

# Clozapine

## Catalog No: tcsc0644

### Available Sizes

**Size:** 100mg

**Size:** 500mg

**Size:** 5g

### Specifications

**CAS No:**
5786-21-0

**Formula:**
$C_{18}H_{19}ClN_4$

**Pathway:**
GPCR/G Protein;Neuronal Signaling

**Target:**
Dopamine Receptor;Dopamine Receptor

**Purity / Grade:**
>98%

**Solubility:**
DMSO : 50 mg/mL (152.99 mM; Need ultrasonic)

**Alternative Names:**
HF 1854

**Observed Molecular Weight:**
326.82

## Product Description

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Clozapine (HF 1854) is an antipsychotic used to treat schizophrenia. Clozapine is a potent antagonist of dopamine and a number of other receptors, with a **$K_i$** of 9.5 nM for **M1** receptor.

IC50 & Target: Ki: 9.5 nM (M1), 51 nM (α2-adrenoceptor), 75 nM (D2)[1]

***In Vitro:*** Clozapine shows the unique property of having antipsychotic action but no Parkinson-like motor side effects. The chemical structure of clozapine facilitates a relatively rapid dissociation from D2 receptors. After short-term occupation of D2 receptors, peak neural activity raises synaptic dopamine, which then displaces clozapine. While clozapine also occupies other types of receptors, they may not have a significant role in preventing parkinsonism. Clozapine is very potent at D2 receptor with a $K_i$ of 75 nM. Clozapine is also potent at the α2-adrenoceptor with a $K_i$ value of 51 nM[1]. Clozapine causes paradoxical downregulation of 5-$HT_{2A}$ receptors. Clozapine also binds to 5-$HT_6$ and 5-$HT_7$ receptors with high affnity[2].

***In Vivo:*** Head-twitch response is decreased and [$^3$H]ketanserin binding is downregulated in 1, 7, and 14 days after chronic clozapine. 5-$HT_{2A}$ mRNA is reduced 1 day after chronic clozapine. Induction of c-fos, but not egr-1 and egr-2, is rescued 7 days after chronicclozapine[3].